Analysts Up-Beat On Xencor's XmAB5871 Despite Phase II 'Placebo Hiccup' in SLE
Executive Summary
Analysts shrugged off mixed topline data from a Phase II study showing Xencor’s lead compound XmAb5871 missed its primary endpoint in systemic lupus erythematosus (SLE), blaming the miss on the number of patients dropping out of the placebo arm of the trial.